Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
This Phase I/IIa clinical study is to test safety and anti-tumor activity of BT062 to define
the best dose in treating patients with relapsed or refractory multiple myeloma with multiple
doses of BT062.